Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) and is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate (a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome.

FilterHomeSignaling PathwaysMetabolismIsocitrate Dehydrogenase (IDH)
Ivosidenib
T36171448347-49-6
Ivosidenib (AG-120) is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) with potential antineoplastic activity. It specifically inhibits a mutated form of IDH1 in the cytoplasm, preventing the formation of the oncometabolite 2-hydroxyglutarate (2 hG), which may induce cellular differentiation and inhibit cellular proliferation in IDH1-expressing tumor cells.
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Hot
DS-1001b
T77411898207-64-1
DS-1001b is an inhibitor of mutant IDH-1 (Isocitrate Dehydrogenase-1)
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Enasidenib
T23461446502-11-9
Enasidenib (AG-221) is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity.
  • $39
In Stock
Size
QTY
Mutant IDH1-IN-2
T121281429176-69-1In house
Mutant IDH1-IN-2 is an inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with an IC50 of 16.6 nM in fluorescence biochemical assay and an IC50 of <22 nM in LS-MS biochemical assay.
  • $58
In Stock
Size
QTY
Vorasidenib
T73071644545-52-7
Vorasidenib (PVM MA) is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC50s = 31.9 and 31.7 nM for IDH1R132H and IDH2R140Q, respectively)
  • $48
In Stock
Size
QTY
Olutasidenib
T163841887014-12-1
Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively).
  • $56
In Stock
Size
QTY
AGI-6780
T18091432660-47-3
AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant.
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
BAY-1436032
TQ00421803274-65-8
BAY-1436032 is a novel, selective and orally available inhibitor of pan-mutant isocitrate dehydrogenase 1 (IDH1).
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Hot
AGI-5198
T21041355326-35-0
AGI-5198 (IDH-C35) is a potent and selective inhibitor of IDH1 R132H and R132C mutants, with IC50 values of 0.07 μM and 0.16 μM, respectively.
  • $31
In Stock
Size
QTY
Mutant IDH1-IN-1
T20431355326-21-4
Mutant IDH1-IN-1 is a potent inhibitor of the mutant IDH1 R132 h, exhibiting an IC50 of less than 0.1 μM.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Mutant IDH1 inhibitor
T161611429180-08-4
Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IHMT-IDH1-053
T78758
IHMT-IDH1-053 (compound 16) is an irreversible inhibitor highly selective for the IDH1 R132H mutant, with an IC50 of 4.7 nM. It preferentially targets IDH1 mutants over wild-type IDH1 and IDH2, in both their wild-type and mutant forms. In 293T cells transfected with the IDH1 R132H mutant, IHMT-IDH1-053 reduces 2-hydroxyglutarate (2-HG) production with an IC50 of 28 nM. The compound binds to the R132H protein at an allosteric site near the NADPH binding region, forming a covalent linkage with Cys269. Additionally, IHMT-IDH1-053 inhibits the growth of both the HT1080 cell line and primary acute myeloid leukemia (AML) cells harboring IDH1 R132 mutations [1].
  • Inquiry Price
Size
QTY
Ranosidenib
T2012372301974-60-5
Ranolisib is an isocitrate dehydrogenase (IDH) inhibitor known for its antitumor activity.
  • Inquiry Price
10-14 weeks
Size
QTY
SH1573
T2002092376068-96-9
SH1573 is an orally active inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2). It selectively targets the mIDH2 R140Q protein with a potent inhibitory effect (IC50=4.78 nmol L), significantly reducing the production of the oncogenic metabolite 2-hydroxyglutarate (2-HG) in animal models, cell lines, serum, and tumors. SH1573 is utilized in the study of acute myeloid leukemia (AML).
  • Inquiry Price
10-14 weeks
Size
QTY
Alternaphenol B2
T83133
Alternaphenol B2, a selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1m), is sourced from the coral-derived fungus Parengyodontium album SCSIO SX7W11. It exhibits inhibitory activity specifically against the IDH1 R132H mutation, with an IC50 of 41.9 μM [1].
  • Inquiry Price
Size
QTY